A detailed history of Principal Financial Group Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 26,510 shares of LYEL stock, worth $36,583. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,510
Previous 58,254 54.49%
Holding current value
$36,583
Previous $129,000 70.54%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$1.3 - $3.01 $41,267 - $95,549
-31,744 Reduced 54.49%
26,510 $38,000
Q1 2024

Apr 29, 2024

SELL
$1.71 - $3.07 $7,970 - $14,309
-4,661 Reduced 7.41%
58,254 $129,000
Q4 2023

Feb 07, 2024

SELL
$1.39 - $2.35 $7,179 - $12,137
-5,165 Reduced 7.59%
62,915 $122,000
Q3 2023

Nov 02, 2023

BUY
$1.45 - $3.35 $11,476 - $26,515
7,915 Added 13.16%
68,080 $100,000
Q2 2023

Aug 07, 2023

BUY
$1.89 - $3.86 $10,470 - $21,384
5,540 Added 10.14%
60,165 $191,000
Q1 2023

May 09, 2023

BUY
$1.97 - $3.58 $11,360 - $20,645
5,767 Added 11.8%
54,625 $128,000
Q4 2022

Feb 09, 2023

BUY
$2.78 - $8.09 $8,801 - $25,612
3,166 Added 6.93%
48,858 $169,000
Q3 2022

Nov 09, 2022

BUY
$5.54 - $8.27 $53,516 - $79,888
9,660 Added 26.81%
45,692 $335,000
Q2 2022

Aug 10, 2022

SELL
$3.68 - $6.8 $43,008 - $79,471
-11,687 Reduced 24.49%
36,032 $235,000
Q1 2022

May 09, 2022

BUY
$5.05 - $7.7 $96,293 - $146,823
19,068 Added 66.55%
47,719 $241,000
Q4 2021

Feb 09, 2022

BUY
$7.13 - $15.19 $204,281 - $435,208
28,651 New
28,651 $222,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $342M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.